Preparing for a New Era in Alopecia Areata Management: Managed
Care Considerations on the Role of New and Emerging
Therapies is a three part webinar series

A continuing medical education activity sponsored by NAMCP and AAMCN

This webinar series will provide critical updates on the advances in the management of Alopecia Areata

These are archives of live webinars held between March 24, 2021 to March 31, 2021
If you participated in any of the live webinars, you are not eligible to claim
credit from the archive of that webinar.

By clicking on each of the titles, you will be able to participate in each part.
It is not required that you participate in all three or in order.

These activities are valid from April 1, 2021 to April 1, 2023


This series is supported by an educational grant from
Pfizer


 
Audience: This activity is intended for healthcare professionals practicing in managed care environments.

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

Description:
Alopecia areata is an autoimmune disease, characterized by hair loss, often patchy, on the scalp, face, or body. People suffering from alopecia areata experience symptoms when immune cells attack healthy hair follicles, causing the hair to fall out, often starting with smooth, round patches. More than half of patients with alopecia areata experience poor health-related quality of life and, as a result, the condition may lead to serious psychological consequences, including high levels of depression and anxiety. Fortunately for patients with this disease, several new treatments are currently undergoing late stage clinical trials, including JAK inhibitors and combinations, that have shown improved efficacy and safety.


A Closer Look at Emerging Therapies in the Management of Alopecia Areata: Managed Care Considerations on JAK Inhibitors in an Evolving Treatment Landscape

  1. Examine the unmet clinical needs in alopecia areata and the impact of inadequately treated disease on physical and mental health, quality of life, costs and work productivity
  2. Assess recent pathophysiological findings in alopecia areata that have informed the study of new therapeutic targets, including JAK inhibitors
  3. Analyze new evidence pertaining to the safety and efficacy of new and emerging therapies in the management of alopecia areata
  4. Explore the role of emerging JAK inhibitors in the management of alopecia areata for patients in all age groups
       Physician, Nursing and CMCN credits valid to April 1, 2023

Reducing the Economic Burden of Alopecia Areata: What Managed Care Needs to Know to About the Health Economics of a Changing Management Paradigm

  1. Examine the unmet economic needs in alopecia areata and the impact of inadequately treated disease on physical and mental health, quality of life, costs and work productivity
  2. Explore the role of emerging JAK inhibitors in the management of alopecia areata for patients in all age groups
  3. Describe approaches currently utilized by third party payers to manage costs associated with the care of patients with alopecia areata
  4. Assess the managed care considerations of new and emerging therapies by exploring where these agents may fit into current alopecia areata management paradigm
  5. Transform therapeutic advances and resource utilization data on emerging therapies in alopecia areata into informed health plan decisions and formulary discussions
       Physician, Nursing and CMCN credits valid to April 1, 2023

A Closer Look at the Clinical, Economic and Developmental Impact of Alopecia Areata: Strategies to Improve Patient Adherence, Quality of Life, and Costs

  1. Explore challenges to patient adherence and quality of life in alopecia areata (AA)
  2. Discuss strategies to implement JAK inhibitors into the treatment paradigm as they are approved, especially as it relates to patient adherence and quality of life
  3. Assess how different biomarkers, comorbidities and adherence barriers play a role in long-term treatment decision making for patients with AA
  4. Review recent clinical trial information around the efficacy and safety of emerging JAK inhibitors currently undergoing clinical studies in AA and their effect on patient quality of life
       Physician, Nursing and CMCN credits valid to April 1, 2023